116644-53-2
基本信息
米貝地爾
米貝地爾(二鹽酸鹽)
CALCIUM CHANNEL抑制劑(MIBEFRADIL DIHYDROCHLORIDE)
RO 40-5967
MIBEFRADIL DIHYDROCHLORIDE
(1S,2S)-2-[2-[[3-(2-Benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate
[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
(1S,2S)-2-[2[[3-(2-BENZIMIDAZOLYLPROPYL]METHYLAMINO]ETHYL]-6-FLUORO-1,2,3,4-TETRAHYDRO-1-ISOPROPYL-2-NAPHTHYL METHOXYACETATE DIHYDROCHLORIDE
Methoxyacetic acid [[(1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropylnaphthalen]-2-yl] ester
Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester
Acetic acid, Methoxy-, 2-[2-[[3-(1H-benziMidazol-2-yl)propyl]MethylaMino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-Methylethyl)-2-naphthalenylester, (1S-cis)-
(1S,2S)-2-[2-[[3-(1H-Benzimidazol-2yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenylmethoxyacetoacetatedihydrochloride
物理化學(xué)性質(zhì)
常見問題列表
IC50: 2.7 μM (T-type calcium channel), 18.6 μM (L-type calcium channel)
Mibefradil inhibits reversibly the T- and L-type currents with IC 50 values of 2.7 and 18.6 μM, respectively. The inhibition of the L-type current is voltage-dependent, whereas that of the T-type current is not. Ro 40-5967 blocks T-type current already at a holding potential of -100 mV At a higher concentration (20 μM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44±16 %) and causes a significant membrane potential depolarisation (from ?83±1 mV to ?71±5 mV). At a higher Mibefradil concentration (20 μM) there is significant membrane potential depolarisation and a slowing of repolarisation. These actions of Mibefradil are consistent with K + channel inhibition, which has been shown to occur in human myoblasts and other cells.
The hearing thresholds of the 24-26 week old C57BL/6J mice differed following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group (P<0.05). Compared with the saline-treated group, rats receiving Mibefradil or Ethosuximide show significant lower Ca V 3.2 expression in the spinal cord and DRG.